Institutional Ownership
United Therapeutics Corp Del
CUSIP 91307C102COMUTHRQ1 2026
Latest EPS (Diluted)
$5.82
Q1 2026 · Mar 31, 2026
Latest Revenue
$781.50M
Reported quarter
Latest Net Income
$274.90M
Reported quarter
Quarters on Record
12
From SEC XBRL filings
Quarterly Earnings
EPS, revenue & net income · SEC XBRL (10-Q / 10-K)
| Period | Quarter | EPS (Basic) | EPS (Diluted) | Revenue | Net Income | Form |
|---|---|---|---|---|---|---|
| Mar 31, 2026 | Q1 2026 | $6.32 | $5.82 | $781.50M | $274.90M | 10-Q |
| Sep 30, 2025 | Q3 2025 | $7.73 | $7.16 | $799.50M | $338.70M | 10-Q |
| Jun 30, 2025 | Q2 2025 | $6.86 | $6.41 | $798.60M | $309.50M | 10-Q |
| Mar 31, 2025 | Q1 2025 | $7.18 | $6.63 | $794.40M | $322.20M | 10-Q |
| Sep 30, 2024 | Q3 2024 | $6.93 | $6.39 | $748.90M | $309.10M | 10-Q |
| Jun 30, 2024 | Q2 2024 | $6.26 | $5.85 | $714.90M | $278.10M | 10-Q |
| Mar 31, 2024 | Q1 2024 | $6.52 | $6.17 | $677.70M | $306.60M | 10-Q |
| Sep 30, 2023 | Q3 2023 | $5.71 | $5.38 | $609.40M | $267.60M | 10-Q |
| Jun 30, 2023 | Q2 2023 | $5.53 | $5.24 | $596.50M | $259.20M | 10-Q |
| Mar 31, 2023 | Q1 2023 | $5.20 | $4.86 | $506.90M | $240.90M | 10-Q |
| Sep 30, 2022 | Q3 2022 | $5.26 | $4.91 | $516.00M | $239.30M | 10-Q |
| Jun 30, 2022 | Q2 2022 | $2.56 | $2.41 | $466.90M | $116.00M | 10-Q |